Do age, fitness, and concomitant medications influence management and outcomes of patients with CLL treated with ibrutinib?
Tedeschi A, Frustaci AM, Mauro FR, Chiarenza A, Coscia M, Ciolli S, Reda G, Laurenti L, Varettoni M, Murru R, Baratè C, Sportoletti P, Greco A, Borella C, Rossi V, Deodato M, Biagi A, Zamprogna G, Pelle AC, Lapietra G, Vitale C, Morelli F, Cassin R, Fresa A, Cavalloni C, Postorino M, Ielo C, Cairoli R, Di Raimondo F, Montillo M, Del Poeta G.
Tedeschi A, et al. Among authors: fresa a.
Blood Adv. 2021 Dec 28;5(24):5490-5500. doi: 10.1182/bloodadvances.2021004824.
Blood Adv. 2021.
PMID: 34525181
Free PMC article.